Pricing Log in Create free account

Aktis Oncology, Inc. (AKTS) vs MeiraGTx Holdings PLC (MGTX)

Aktis Oncology, Inc. and MeiraGTx Holdings PLC are both Biotechnology companies. Aktis Oncology, Inc. and MeiraGTx Holdings PLC are of similar size ($826.0M and $817.3M). Aktis Oncology, Inc. has negative trailing earnings, so its P/E is not meaningful; MeiraGTx Holdings PLC trades at 11.8×. MeiraGTx Holdings PLC has the higher net margin (19.9% vs −782.0%) and the higher return on invested capital (66.6% vs 0.00%). Across the 16 metrics below, MeiraGTx Holdings PLC leads on 12 and Aktis Oncology, Inc. on 4.

Valuation

Metric AKTS MGTX Biotechnology median
P/E n/m 11.83 10.60
P/S 90.34 2.07 9.40
P/B 1.80 3.81 2.13
Price to free cash flow n/m 81.19 25.18
EV/EBITDA n/m 3.94 0.66
EV/Sales 36.79 1.96 9.02
Earnings yield (264.93%) 8.45% (32.88%)
Free cash flow yield (15.97%) 1.23% (23.13%)

Profitability

Metric AKTS MGTX Biotechnology median
Gross margin 100.00% 97.95% 68.51%
Operating margin (939.13%) 46.30% 0.00%
Net margin (781.95%) 19.87% 0.00%
Free cash flow margin (1,442.91%) 2.55% 0.00%
Return on equity (34.45%) 72.22% (51.96%)
Return on assets (22.22%) 26.54% (46.06%)
Return on invested capital 0.00% 66.60% 0.00%

Growth

Metric AKTS MGTX Biotechnology median
Revenue growth (TTM) — 948.35% 6.76%
EPS growth (last fiscal year) (25.43%) 33.02% 29.88%
Revenue growth, 5-year CAGR — 39.22% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric AKTS MGTX Biotechnology median
Debt to equity 0.00 0.46 0.00
Current ratio 16.33 3.76 4.97
Net debt to EBITDA 2.95 0.18 1.01

Dividend

Metric AKTS MGTX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AKTS MGTX Biotechnology median
Market cap 825.95m 817.32m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack